Mahesh Parmar

Sarojini Naidu Medical College — India

Mathematics · Physical Sciences

103h-index57.4kcitations555works6.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Statistical Methods in Clinical Trials(122), Prostate Cancer Treatment and Research(110), Ovarian cancer diagnosis and treatment(77), Health Systems, Economic Evaluations, Quality of Life(63), Meta-analysis and systematic reviews(52)

Publications547 total

TRANSFORMATIVE SOCIAL WORK: APPROACHES AND CASE INSIGHTS FOR LGBTQIA+ COMMUNITY EMPOWERMENT
Journal of Applied Bioanalysis·2025Open Access
LBA93 First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL
Annals of Oncology·2025· 1 cited
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
Cell·2025· 13 citedOpen Access
EVALUATION OF MIDDLE EAR CLEFT STATUS IN PATIENTS OF TUBOTYMPANIC SAFE TYPE OF CSOM UNDERGOING TYMPANOPLASTY WITH CORTICAL MASTOIDECTOMY
GLOBAL JOURNAL FOR RESEARCH ANALYSIS·2025
Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials
European Urology Open Science·2025· 1 citedOpen Access
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
The Lancet Oncology·2025· 12 citedOpen Access
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol
The Lancet Digital Health·2025· 10 citedOpen Access
Tackling control risk problems in non-inferiority trials
BMJ Medicine·2025Open Access
Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.
Journal of Clinical Oncology·2025
Determining the optimal use of approved drugs in oncology
The Lancet Oncology·2025· 4 cited
Sharing clinical trial results with participants: important, expected and possible
Trials·2025· 3 citedOpen Access
Developing an adaptive platform trial for evaluation of medical treatments for Crohn’s disease
Nature Reviews Gastroenterology & Hepatology·2025· 1 cited
858 Evaluating Cribriform Pattern with Clinical Outcomes in the STAMPEDE Cohort of Primary Advanced Hormone Sensitive Prostate Cancer
Laboratory Investigation·2025Open Access
A0516 – Metabolic benefits of adding metformin to androgen deprivation therapy for patients with metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Results from the STAMPEDE metformin trial
European Urology·2025
Plasma <i>AR</i> Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer
JAMA Oncology·2025· 3 citedOpen Access
<i>HSD3B1</i> and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus prednisolone (AAP) STAMPEDE phase 3 trial.
Journal of Clinical Oncology·2025
Transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT): Efficacy and safety of combining with androgen receptor pathway inhibitors (ARPIs) in metastatic (M1) prostate cancer—Randomised comparison from the STAMPEDE trial platform.
Journal of Clinical Oncology·2025· 4 cited
Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).
Journal of Clinical Oncology·2025· 12 cited
Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS
EBioMedicine·2025· 10 citedOpen Access
Effect of feeding green Agathi (Sesbania grandiflora) and Stylo (Stylosanthes hamata) leaves on growth performance of Osmanabadi kids under different management systems
International Journal of Research in Agronomy·2025Open Access
page 1 of 28Next →

Frequent Co-authors

Matthew R. Sydes(12), Richard Stephens(10), Nicholas D. James(8), Gunnar B. Kristensen(7), Noel W. Clarke(7), David P. Dearnaley(7), Christopher Parker(7), John M. Russell(7), Malcolm D. Mason(6), Matthew Nankivell(6), Jonathan A. Ledermann(5), A.W.S. Ritchie(5), William Cross(5), Robert J. Jones(5), Joanna Gale(5), Joe M. O’Sullivan(5), Éric Pujade-Lauraine(4), Andrés Cervantes(4), Gerhardt Attard(4), Claire Amos(4)